chrisvoncsefalvay/vaers-outcomes huggingface dataset:
From April 13th to current date I have a skin rashes that have been confirmed by two doctors that it is dertmatographism.  My skin becomes extremly itchy and red marks appear.  I also ha an area on the left side of my face which produces small red bumps.   I have been instructed to increase my daily inake of Zytrec to two times a day vs. one.
Debilitating headaches, nausea,blurred vision, weakness, palpitations, twitching on lower leg.
retinal issues; affect hearing; severe rash; Information has been received regarding a case in litigation from a lawyer and referred to a male patient (pt) of unknown age. No information was provided regarding the pt's medical history, allergies, drug reactions, concurrent conditions or concomitant medications. On or around 14-MAY-2016, the pt received the zoster vaccine live (ZOSTAVAX) (route, strength, dose, lot number and expiration date were unknown) from a pharmacy for its intended purpose: the prevention of shingles. On unknown date (reported as shortly thereafter), the pt suffered severe side effects affecting his vision and hearing in addition to a severe rash. The pt presented to physician and was diagnosed with retinal issues and had eye surgery. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, the pt's symptoms have resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX) product. The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of his condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the pt sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the pt suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. The pt had incurred and would continue to incur medical expenses and other economic harm as a direct result of use of zoster vaccine live (ZOSTAVAX). The outcome of the events was considered as not recovered. The causality was related.   The reporter considered the events to be disability.
Patient complained about being nauseous and then shortness of breathe.  Then by the time her aid was able to call 911 for help she died.
At Hepatitis A clinic, box of pediatric vaccine in cooler instead of Adult dose. Dose taken out and given. Revaccinated on 11-2-2018 with adult Hepatitis A VAQTA, R018775, 2019Aug09, in Right Deltoid.
10/08/10: TC from patient: On 9/30 she received a seasonal flu shot where she gets her flu shot every year. The injection was painless, but about 10 minutes later she began to develop prickling and pain at the site. This moved up her arm to her shoulder, neck and base of the skull. The intensity would vary, but at times it gave her nausea. This went on for about 36 hours, then slowly resolved in reverse order, e.g., her head felt better first. TYLENOL and ice packs helped.
approx 1hr after vaccine - became hot. weak & mother states "gray" face - called ambulance - was see in ER. - dehydration received IVF & WBC count was elevated
Information has been received from a health professional concerning a 5 year old female with no pertinent medical history and known drug allergies who on 06-AUG-2007, received a first dose of varicella virus live vaccine (Oka/Merck). She developed chicken pox, and on 06-MAR-2008, she presented to the office for exam with greater than 50 lesions. The lesions were located behind each ear, on the back of the neck and on the front and back of her torso. No treatment was prescribed, and no laboratory or diagnostic studies were performed. It was noted that the child was kept out of school until all the lesions were scabbed over. The Nurse indicated that the patient would not be receiving a second dose of varicella virus vaccine live (Oka/Merck) due to the chicken pox outbreak. A product quality complaint was not reported. Additional information has been requested. This is in follow-up to report(s) previously submitted on 05/16/2008. Information has been received from a health professional concerning a 5 year old 33 lb. 41 1/4 in, female with no pertinent medical history and known drug allergies who on 06-AUG-2007, received a first dose of VARIVAX. There was no reported illness at the time of vaccination. It was noted that on 11-SEP-2007), she received a second dose in the right upper thigh of MMR (lot# "1410F"). She developed chicken pox, and on 06-MAR-2008 at 13:00 hours, she presented to the office for a sick visit exam with greater than 50 lesions. The lesions were located behind each ear, on the back of the neck, and on the front and back of her torso. No treatment was prescribed, and no laboratory or diagnostic studies were performed. It was noted that the child was kept out of school until all the lesions were scabbed over. The Nurse indicated that the patient would not be receiving a second dose of VARIVAX due to the chicken pox outbreak. On 12-MAR-2008, she had recovered. A product quality complaint was not reported. Additional information is not expected.
Information has been received from a female concerning her daughter, for a pregnancy registry for GARDASIL, who on an unspecified date was vaccinated with the first dose of GARDASIL. The reporter stated that the patient did not know at the time of the vaccination that she was pregnant. The patient had the baby 3 weeks after the vaccination. It was reported the patient sought unspecified medical attention. It was reported that the baby died. The patient was 9 weeks pregnant. Upon internal review, baby died at 9 weeks was determined to be an other important event. No further information is available.
Information has been received from a nurse concerning a 16 year old female (ptreviously reported as 15 year old) with no illness at the time of vaccination and no pre-existing illness or allergies who on 02-MAR-2007 (previously reported as 09-MAR-2007) was vaccinated with first dose of Gardasil (lot# 657006/0188U). 0.5 ml once IM in the left deltoid at 5:15 PM.   On 02-MAR-2007, after receiving the injection, the patient fainted and fell from the chair where she was sitting. Medical attention was sought. However, she regained consciousness after five minutes. She went home after the recovery. No further information was available at the time of reporting. Additional information has been requested.  Additional infromation was received from a licensed vocational nurse. On 02-MAR-2007, at 5:15 PM after receiving the vaccination the patient stated that she felt lightheaded and fell forward and laid her head on the nurses shoulder. The patient then briefly had a "seizure like" motion of her head. The nurse laid her back on the table. The patient quickly resumed normal fucntion and stated she felt fine. The physician stated vasovagal episode.  No additional information is expected.
Dizziness, HYPERtension, Tachycardia, numbness of tonuge Narrative: Employee received booster dose of Moderna, she came back one later complaining of dizziness and tongue  numbness.
Pt vaccinated with DTP/OPV 2 days later baby stopped breathing, turned black around mouth. Aunt shook baby awake. Seen by MD admitted to hosp for apnea monitor.
Information regarding PREVNAR was received from a healthcare professional regarding a 53 year old female patient who experienced pain in shoulder, pain in back of neck, inappropriate use of drug, spasms and swelling to her collar bone. The patient received a dose on 16 Sep 2010. The patient also received a dose of PNEUMOVAX on 16 Sep 2010. The patient's concurrent illnesses included chronic sinusitis and fibromyalgia. Past therapies included PNEUMOVAX . Indication for PREVNAR was immunization. Product was administered on 16 Sep 2010. Dose regimen was 1 dose 1 time per day. Concomitant medications were not reported. The patient experienced pain in shoulder, pain in back of neck, inappropriate use of drug, spasms and swelling to her collar bone in 2010. Sometime in 2010, patient saw a rheumatologist and was provided with an unspecified pain medication and went for physical therapy. Because of persisting symptoms, she also went to see an orthopedist who is calling her symptoms neuropathy. As of 18 Oct 2010, the patient's symptoms persist but are less. X ray (results: normal results) and laboratory test (results: unspecified (normal results)) were done in 2010. No additional information was available at the time of this report.
DIED; BRAIN FILLED WITH BLOOD CLOTS; VERTIGO LIKE SYMPTOMS; This spontaneous report received from a consumer via a company representative via social media concerned a male of unspecified age, race and ethnicity. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: Unknown) dose was not reported, 1 total, start therapy date were not reported, administered for prophylactic vaccination (Dose number in series 1). The batch number was not reported. The Company is unable to perform follow-up to request batch/lot number. No concomitant medications were reported. On an unspecified date, the patient experienced brain filled with blood clots, vertigo like symptoms and died from unknown cause of death. Reporter Stated as " My brother died after receiving the jab! He developed Vertigo like Systems. His brain was filled with Blood clots" It was unspecified if an autopsy was performed or not. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of vertigo like symptoms and brain filled with blood clots was not reported. This report was serious (Death, and Other Medically Important Condition). This case, from the same reporter is linked to 20211260953 and 20211260743.; Sender's Comments: V0:  20211261664-covid-19 vaccine ad26.cov2.s- Died, Brain filled with blood clots. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).; Reported Cause(s) of Death: UNKNOWN CAUSE OF DEATH
MA gave 5-11 incorrectly.  Pt should have received 12+ as the child was age 12 on 10-26-2022.  VAERS report filed.
PATIENT REPORTED SEVERE BLURRED VISION COMING ON 4-5 HOURS AFTER RECEIVING VACCINE, EVENT LASTED ABOUT 15 MINUTES COMPLETELY LIMITING VISION, THEN RESOLVING FOR THE MOST PART. STILL FEELING LIKE FOCUSING TO READ IS MORE DIFFICULT.
Abdominal pain.  Felt like i was full. Was upper left quadrant abdominal.  Couldnt eat or drink much without pain.
Breakthrough Covid infection. Patient received Pfizer vaccine on April 28th and May 17th, and presented with active COVID infection 8/18/2021. Symptoms first started 8/16/2021 with headache, cough, nasal congestion, bodyaches, shortness of breath. Respiratory panel positive for SARS-CoV-2 PCR.
Patient had first SHINGRIX shot (9/14/2018) in left arm and experienced soreness for 3-4 days. In this case, patient received the 2nd SHINGRIX vaccine (12/05/2018) in the right arm and patient first contacts pharmacy on 12/21/2018 complaining of redness, limited use of arm, soreness mainly between shoulder and elbow but also under the arm. She states the pain occurs at different places at different times, and patient states on 01/08/2018 that symptoms still remain except the redness which has since resolved.
On 09/20/01 HD MD -Left upper arm swollen almost to 2 X normal size from elbow to shoulder with some swelling above shoulder. In the area of the injection there is  increased erythema and multiple tiny vesicles. Instructed to go to PCP today. Mother states they went to ER and 3 different doctors looked at child without knowing the problem. Chest x-ray and CBC done. Pt prescribed oral antibiotics and topical ointment for arm.
FEVER; This spontaneous report received from a patient via a company representative via social media (J and J Corporate) concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, 1 total administered on an unspecified date in 2021 for covid-19 prophylaxis. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date in 2021, the patient experienced fever for 3 days (dose number in series 1). As per reporter, "I had the j and j shot and the fever for 3 days. then I got the moderna boost. a year ago". The patient additionally received Moderna covid-19 vaccine (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, administered on an unspecified date in 2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse event following vaccination with Moderna covid-19 vaccine (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on 2021. This report was non-serious.
pt states she had chills, upset stomach, and night sweats.  After a week she had a weird itching sensation that ran down the front of both arms and she got sore achy muscles down her back.   About 16 days later she woke up with an uncontrollable cough that was continuous to where she couldnt catch her breath, like she was choking.  This lasted about 5 minutes till she could finally clear her throat.  She called it a Covid Cough.  She said this disappeared after 20 minutes.  She said it was the strangest thing and it hasnt happened again since then.  Three weeks later she was exposed to COVID since having both vaccines and is doing well.  She said the CDC could contact her for a vaccine study purposes if necessary.
Information has been received from a physician concerning her 15-month-old daughter who at 1 year of age (on approximately 11-DEC-2005) was vaccinated with a dose of varicella virus vaccine live. ON approximately 14-MAR-2006 the patient developed a breakthrough rash with no other symptoms, no fever. Unspecified medical attention was sought and she was diagnosed with chickenpox. At the time of this report the patient was recovering without treatment. The physician also reported that her other daughter experienced chickenpox following vaccination with varicella virus vaccine live (associated WAES # 0603USA00757). Additional information has been requested.   This is in follow-up to report (s) previously submitted on 5/12/2006.  Information has been received from a physician concerning her 27-month-old daughter with no pre-existing allergies, birth defects or medical conditions, who at 1 year of age (on approximately 11-DEC-2005) was vaccinated with a dose of VARIVAX (Merck).  On approximately 14-MAR-2006 the patient developed a breakthrough rash with no other symptoms, no fever.  Unspecified medical attention was sought and she was diagnosed with chickenpox.  At the time of this report the patient was recovering without treatment.  The physician also reported that her other daughter experienced chickenpox following vaccination with VARIVAX (Merck) (associated WAES # 0603USA00757).  Additional information has been received on 26-APR-2006 from the physician.  She indicated that on 03-FEB-2005 at 16:00, her daughter was vaccinated in the right thigh with her first dose of VARIVAX (Merck) (lot # "UE714AA").  There was no illness at the time of vaccination.  There were no concomitant medications.  About 1 1/2 weeks after the onset of her sister's rash (WAES # 0603USA00757), on 09-MAR-2006, she developed a varicella rash of about 5-10 lesions.  It was reported that she recovered as of 12-MAR-2006.  No additional information is expected.
On 5/7/01, at 20:00, complained of pain of left thigh, swelling and redness, felt warm and did not feel well. On 5/8/01, pt did not want to walk on leg due to pain with increased swelling and redness. On 5/9/01, was able to walk.
I have experienced common side effects such as headache, body aches, and soreness at the injection site.  Additionally, I have notable soreness and inflammation in my breasts.  I have silicone breast implants from an augmentation procedure current year.  The augmentation was performed for cosmetic purposes only.
EXPIRED VACCINE ADMINISTERED; This spontaneous report received from a pharmacist concerned a 52 year old male of unspecified race and ethnic origin. The patient's height, and weight were not reported. Patient did not report any illness at the time of vaccination. Patient had no history of similar event, had no adverse events related to previous vaccinations, no history of allergy to vaccine, drug, or food. Patient did not report any history of pre-existing acute illness 30 days prior to vaccination. Patient had no history of hospitalization and had no family history of any disease. On 29-APR-2021, the patient was previously vaccinated with covid-19 vaccine ad26. cov2.s (dose number in series: 1) (suspension for injection, intramuscular, batch number 1805029, expiry: unknown) 1 total, to left arm for prophylactic vaccination. It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26. cov2.s (dose number in series: 1).  The patient received covid-19 vaccine ad26.cov2.s (Dose number in series: 2) (suspension for injection, intramuscular, batch number: 211A21A, and expiry: 14-DEC-2021) dose was not reported, 1 total, administered to the left arm on 21-DEC-2021 for prophylactic vaccination. The vaccine was stored at 2-8 degrees Celsius. The vaccine was removed thrice from the storage and kept out for 10 minutes. Then returned to refrigerator. The gauze/length of the needle was 25G, 1 inch. No concomitant medications were reported.  On 21-DEC-2021, the patient received expired vaccine (Dose number in series: 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20220210382, 20220260967, 20220261000, 20220261011, 20220261042, 20220261024, 20220261063, 20220261039, 20220261092, 20220261014 and 20220260995.
I started developing tremors in my left arm two months after I got the shot. Eventually a neurologist diagnosed with functional movement disorder. I have researched that COVID vaccines can cause FMD and maybe that is why I was diagnosed with it.  When my tremors were so bad I thought of going on disability.
Sore arm after injection; This is a spontaneous report received from a non-contactable consumer. A male patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration on an unknown date for COVID-19 immunisation. Medical history and concomitant medication was not reported. On an unknown date, the patient experienced sore arm after injection. The clinical outcome of the event sore arm was unknown at the time of reporting. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient reports constant pain in/around injection site since receiving vaccine, and injection site reaction (redness) which lasted around 1 day, which she has not previously experienced with this vaccine
Couple hours after 2nd vaccine tinnitus  started; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6200) via an unspecified route of administration in the right arm on 02Mar2021 as a single dose for COVID-19 immunisation. Medical history included allergic seasonal allergy, and hypothyroidism. Prior to vaccination, patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine sodium (SYNTHROID) from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: El9267) via an unspecified route of administration in the left arm on 09Feb2021 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Mar2021 the patient experienced tinnitus. Therapeutic measures were taken as a result of tinnitus which included treatment with Aleve. The adverse event resulted in doctor or other healthcare professional office or clinic visit. Since the vaccination, patient had not been tested for COVID-19. The clinical outcome of the event tinnitus was unknown at the time of this report.
CHILD HAD SWEELING ON AREA AROUND EYES AND POSSIBLE FACIAL SWELLING
Soreness in the arm that received the vaccination; This is a spontaneous report from a contactable consumer. A 12-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0185) via intramuscular route of administration in the left arm on 16May2021 at 09:30 (at the age of 12-years-old) as a single dose for COVID-19 immunisation. The patient had medical history of known allergies to Lactose intolerance. Concomitant medication included tilactase (LACTAID) from an unknown date for unknown indication. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 16May2021 at 17:00, the patient experienced soreness in the arm that received the vaccination. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of soreness in the arm that received the vaccination was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Patient presented redness over a 3 inch radius around injection site. The onset was 12 hrs after administration and lasted for 5 days. Patient started to apply Benadryl cream (OTC) on day 2 and the redness subsided by the 5th day.
Abdominal pain, nausea, and diarrhea and rash. No fever
This spontaneous report as received form registered nurse refers to a 23 year old unknown gender patient. On 08-JUL-2013 the patient was vaccinated with GARDASIL injection, first dose (lot number and expiry date unspecified), 0.5 ml, intramuscularly. On 18-OCT-2013, second dose of GARDASIL with lot 1745AA expiry date 13-SEP-2014 was administered and no adverse events were reported. The outcome of the event was reported as unknown. This case # 1402USA000389 is linked with case # 1401USA014451 via same reporter link. Additional information has been requested.